BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...the ultimate conditional gene knockout.” Stew Fisher, C4 Therapeutics...
...get different degradation endpoints,”  Stew Fisher, CSO of C4 Therapeutics Inc....
...Hippel-Lindau tumor suppressor Karen Tkach Tuzman Arvinas Inc. Kymera Therapeutics Inc. C4 Therapeutics Inc. Nurix...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings. Shares of C4 Therapeutics Inc....
...IKAROS family zinc finger 3SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos Oncorus Inc. C4 Therapeutics Inc. Foghorn...
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...By BC Staff It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...could enter the IPO queue before long. C4 Therapeutics Inc....
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...targets and modalities. For example, in January 2019, the company partnered with protein degradation play C4 Therapeutics Inc....
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...of Growing Up” ). Another preclinical company in the area could soon enter the queue. C4 Therapeutics Inc....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...Chicko, who stepped down from the growth factor modulation company in October. Protein degradation company C4 Therapeutics Inc....
...Sialic acid binding Ig like lectin 15 Robin Sawka, BioCentury Staff Waters Corp. Vertex Pharmaceuticals Inc. Turning Point Therapeutics Inc. C4 Therapeutics Inc. Scholar...
BioCentury | Jul 10, 2020
Deals

Data Bytes: Kymera-Sanofi deal is latest sign targeted degradation is growing up

...a potential total value of $2.6 million. Between them, Kymera, Nurix, Arvinas Inc. (NASDAQ:ARVN) and C4 Therapeutics Inc....
...U.S. Targets IRAK4 - Interleukin-1 receptor-associated kinase 4 Karen Tkach Tuzman, Associate Editor Kymera Therapeutics Inc. Sanofi Arvinas Inc. Nurix Inc. C4 Therapeutics Inc. targeted...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...of COVID-19, the IPO queue has fattened up lately (see “Daily Chart: IPO Queue” ). C4 Therapeutics Inc....
...studies for a CF program, 4D-710. Meredith Durkin Wolfe contributed to this report. Paul Bonanos, Associate Editor C4 Therapeutics Inc. 4D...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...ChEM-H) institute. Gray leads Dana-Farber’s Center for Protein Degradation with Eric Fischer; he also co-founded C4 Therapeutics Inc....
Items per page:
1 - 10 of 49
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...the ultimate conditional gene knockout.” Stew Fisher, C4 Therapeutics...
...get different degradation endpoints,”  Stew Fisher, CSO of C4 Therapeutics Inc....
...Hippel-Lindau tumor suppressor Karen Tkach Tuzman Arvinas Inc. Kymera Therapeutics Inc. C4 Therapeutics Inc. Nurix...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings. Shares of C4 Therapeutics Inc....
...IKAROS family zinc finger 3SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos Oncorus Inc. C4 Therapeutics Inc. Foghorn...
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...By BC Staff It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...could enter the IPO queue before long. C4 Therapeutics Inc....
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...targets and modalities. For example, in January 2019, the company partnered with protein degradation play C4 Therapeutics Inc....
BioCentury | Aug 4, 2020
Finance

Interest in protein degradation runs hot as Kymera files for IPO

...of Growing Up” ). Another preclinical company in the area could soon enter the queue. C4 Therapeutics Inc....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

...Chicko, who stepped down from the growth factor modulation company in October. Protein degradation company C4 Therapeutics Inc....
...Sialic acid binding Ig like lectin 15 Robin Sawka, BioCentury Staff Waters Corp. Vertex Pharmaceuticals Inc. Turning Point Therapeutics Inc. C4 Therapeutics Inc. Scholar...
BioCentury | Jul 10, 2020
Deals

Data Bytes: Kymera-Sanofi deal is latest sign targeted degradation is growing up

...a potential total value of $2.6 million. Between them, Kymera, Nurix, Arvinas Inc. (NASDAQ:ARVN) and C4 Therapeutics Inc....
...U.S. Targets IRAK4 - Interleukin-1 receptor-associated kinase 4 Karen Tkach Tuzman, Associate Editor Kymera Therapeutics Inc. Sanofi Arvinas Inc. Nurix Inc. C4 Therapeutics Inc. targeted...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...of COVID-19, the IPO queue has fattened up lately (see “Daily Chart: IPO Queue” ). C4 Therapeutics Inc....
...studies for a CF program, 4D-710. Meredith Durkin Wolfe contributed to this report. Paul Bonanos, Associate Editor C4 Therapeutics Inc. 4D...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...ChEM-H) institute. Gray leads Dana-Farber’s Center for Protein Degradation with Eric Fischer; he also co-founded C4 Therapeutics Inc....
Items per page:
1 - 10 of 49